CONTACT

Direction

Christophe CAUX

christophe.caux
@lyon.unicancer.fr


Cheney D - 3rd floor
Centre Léon Bérard
28 rue Laennec
69373 Lyon Cedex 08
France
CAUX Christophe
Chef d'équipe
DEPIL Stéphane
Praticien hospitalier (CLB)
stephane.depil@lyon.unicancer.fr
DORE Jean-François
BACHELOT Thomas
Praticien hospitalier CLB   
thomas.bachelot@lyon.unicancer.fr
DUBOIS Bertrand
MICHALLET Marie-Cécile
MENETRIER-CAUX Christine
BENDRISS-VERMARE Nathalie
VALLADEAU-GUILEMOND Jenny
RODRIGUEZ Céline
DOFFIN Anne-Claire
MOUDOMBI Lyvia
POUJOL Dominique
Technicienne CLB    
dominique.poujol@lyon.unicancer.fr
BERTHET Justine
Ingenieure d'études INSERM
justine.berthet@lyon.unicancer.fr
HUBERT Margaux
DI ROIO Anthony
BONAVENTURA Paola
VOISSIERE Aurélien
ALCAZER Vincent
LOUNICI Yasmine
SARABI Matthieu
ARDIN Maude
PENEL-PAGE Mathilde
PEREIRA-ABRANTES Manuela
MUTEZ Virginie
BESSON Laurie

Ingénieure d'Etudes
laurie.BESSON@lyon.unicancer.fr

Voir les objectifs et projets Voir les publications

OBJECTIVES

While immune evasion mechanisms in established tumors start to be well characterized, the very early events that permit pre-neoplasic cell detection remain poorly understood. Although diverse innate immune cells likely contribute to tumor sensing, it’s mainly cellular stress detection by NK cell through NKG2D/NKG2DL interaction that is so far established to mediate tumor recognition. Our project will focus on Breast Cancer (BC) and Colon carcinoma and use unbiased system biology and biologically-driven approaches, both in human and mice, to identify important mechanisms of immune sensing of the very early stages of cell transformation. The team project is guided by 2 major complementary concepts: i- existence of tumor cell intrinsic mechanisms of innate detection of cell transformation, ii- cooperation of dendritic cells (DC) with other innate cells to sense cell transformation and initiate adaptive immunity. It is expected that understanding mechanisms of early immune detection of cell transformation will yield to the discovery of important novel escape mechanisms that could be targeted in established tumors.

Thus, our team analyze Innate immune surveillance mechanisms with groups of Drs Marie-Cécile Michallet, Nathalie Bendriss-Vermare, Jenny Valladeau-Guilemond, and Isabelle Puisieux and adaptive immune surveillance and resistance mechanisms with groups of Drs Bertrand Dubois, Christine Ménétrier-Caux, and Stephane Depil.


We have hypothesized that innate immune surveillance is initiated early during transformation through oncogenic stress. This is supported in mouse model showing that expression of an oncogenic signal (HrasV12) induces innate immune cell recruitment required for tumor clearance (Xue, 2007, Kang, Nature 2011). To decipher the underlying mechanisms in vitro in human and in vivo in mice, we have developed approaches based on mammary epithelial cell lines expressing an inducible oncogene (Her2, Rasv12). In a mouse mammary tumor model where oncogenic stress leads to tumor rejection in immunocompetent (wt) mice but not in immunodeficient mice, an unbiased genome editing in vivo screen will be performed to select tumor clones developing in wt mice and to discover molecular pathways operating in the tumor cell leading to immune detection

Many innate immune cells such as dendritic cells (DC) and neutrophils contribute to the tumor immune surveillance. Our previous work and preliminary results have shown that :

i) pDC contribute to this surveillance process by sensing TLR-dependent signals in cooperation with neutrophils. This immune surveillance is counteracted in established tumors through several resistance mechanisms.

ii) another particular subset of DC named BDCA3+/XCR1+ DC infiltrate human tumors, produce IFN-III (IFNl), and, in cooperation with NK cells, have the unique capacity to cross-present cell-associated Ag from living cells to CD8+ T cells

iii) IL-33 detected in the tumor environment is a potent IFNg inducer by NK cells.

Thus, based on these data and on the concept that the innate immune system needs to be alerted through different pathways or cells, we hypothesize that pDC/neutrophils and IL-33/XCR1+ DC/NK cells cooperate to sense early stages of cell transformation and to induce adaptive immunity through cross-presentation to CD8+ T cells.

We thus analyze human early tumor lesions where we perform a comprehensive analysis of the functional/activation status of DC subsets, neutrophils, and NK cells in early (Hyperplasia and In Situ breast cancer and Colon polyps) compared to invasive tumors by multiparametric flow cytometry, deep scRNAseq and multi-immunofluorescence. Second, we performed same analysis of immune infiltrating cells in a mouse early mammary tumor model and using many transgenic mice.

Concerning adaptive immune surveillance, the team made several original observations suggesting the importance of the underexplored humoral response in tumor immune surveillance and the existence of novel classes of neo-antigens. The differential impact of B cell populations, TLS and Ig isotypes on tumor immune surveillance and efficiency of immunotherapy, and their antigenic targets will be deciphered using prospective and retrospective cohorts of patients using cytometry, multi-IF staining, RNAseq and peptide arrays. We recently showed for example that tumors associated to paraneoplastic neurologic diseases (rare autoimmune disorders satellite to a cancer), present genomic alterations in onconeural Ags (collab J. Honnorat, INMG, Lyon), resulting in tolerance breakdown and to efficient anti-tumor immune response against the created neo-epitopes and massive infiltration by plasma cells and CD8+ cytotoxic T cells.

Finally, concerning immune resistance mechanisms, we will mainly i) pursue biological investigations on adenosine pathway and ii) take advantage of ongoing immunotherapy clinical trials to identify novel immune resistance pathways. Indeed, we have identified CD4+ CD73+ potent polyfunctional anti-tumor effector T cells (Teffs) whose function is selectively blocked in the tumor environment by CD39+ Treg through CD39/CD73 produced immunosuppressive adenosine. We will thus analyze: i) the accumulation of CD73+ Teffs upon neo-adjuvant chemotherapy in patients, ii) their frequency and functional status in anti-PD-1/L1 treated patients, iii) the impact of combined anti-PD1 and anti-CD73 neutralizing mAbs or allosteric inhibitors in preclinical humanized mouse models.

In the objective to identify targetable resistance mechanisms in TNBC and ovarian tumors in particular, we will perform a comprehensive comparison of tumors from responding versus non-responding IT-treated patients (trials NeoPembrOV, Breast-Immun-3, and Chemo-Immune) through i) total RNAseq, ii) single cell RNAseq of both tumor and immune cell subsets, iii) nanostring DSP (Digital Spatial Profiling microscopy) single cell in situ analysis to generate spatial data. Through multiscale data integration (collab Synergie Lyon Cancer, Bio-informatic Platform ‘Gilles Thomas’), we expect to identify novel pathways of immune resistance. As for past programs, identified targets will be pursued for drug development and immune intervention (C3D & biotech partnership).



COLLABORATION AND FOUNDING

Financial support
INSERM and CNRS
Université Claude Bernard Lyon I 
Institut National du Cancer (INCa) 
Association pour la Recherche sur le Cancer (ARC) 
Ligue Nationale contre le Cancer (Comités de l’Ain, de l’Ardèche, de la Drôme, du Puy de Dôme, du Rhône, de Savoie et de Saône et Loire) 
Agence Nationale pour la Recherche
Région Auvergne Rhône-Alpes
Lyon Biopole 
Laboratoire d'Excellence (LabEx) DevWeCan (Grand Emprunt) 
Fondation pour la Recherche Médicale (FRM) 

National Collaborations
Institut Gustave Roussy (Villejuif) / Laurence ZITVOGEL 
INSERM U851 (Lyon) / Jacqueline MARVEL et Thierry WALZER 
Institut de Recherche Thérapeutique IRT UN Unité INSERM 892, Centre de Recherche en Cancérologie Nantes-Angers (Nantes) / Henri VIE 

> MORE INFORMATION

PUBLICATIONS

 2019

 

  1. Burlion A, Ramos RN, Pukar KC, Sendeyo K, Corneau A, Ménétrier-Caux C, Piaggio E, Olive D, Caux C and Marodon G. (2019) A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system. OncoImmunology In press
  2. Ménétrier-Caux C, Ray-Coquard I, Blay JY, Caux C. (2019) Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? Journal of Immunotherapy of Cancer In press
  3. Ouaguia L, Leroy V, Dufeu-Duchesne T, Durantel D, Decaens T, Hubert M, Valladeau-Guilemond J, Bendriss-Vermare N, Chaperot L, Aspord C. (2019) Circulating and hepatic BDCA1+, BDCA2+, and BDCA3+ dendritic cells are subverted in patients with chronic HBV infection. Front Immunol. 2019 Feb 4;10:112.
  4. Sciarra A, Monteiro I, Ménétrier-Caux C, Caux C, Gilbert B, Halkic N, La Rosa S, Romero P, Sempoux C, de Leval L. (2019) CD73 expression in normal and pathological human hepatobiliopancreatic tissues. Cancer Immunol Immunother. Janv. 4. doi: 10.1007/s00262-018-2290-1.
  5.  Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilermond J, Valsesia-Wittmann S, Amigorena S. et al.  (2019) Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019 Feb 8;10:168.
  6. Alcazer V, Bonaventura P, Tonon L, Wittmann S, Caux C, Depil S. (2019) Neoepitopes-based vaccines: challenges and perspectives. Eur J Cancer Janv 12;108:55 60.

2018

 

  1.  Depil S, Bonaventura P, Alcazer V, Tonon L. (2018) Nouvelles approches vaccinales en cancérologie. Bull Cancer (Paris). 105:S113 20.
  2. Alcazer V, Delenda C, Poirot L, Depil S. (2018) Développement des CAR-T dans les tumeurs solides. Bull Cancer (Paris). 105:S15 24.
  3.  Tout I, Gomes M, Ainouze M, Marotel M, Pecoul T, Durantel D, Vaccarella S, Dubois B, Loustaud-Ratti V, Walzer T, Alain S, Chemin I, Hasan U. (2018) Hepatitis B Virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B Cells. J Immunol. Oct 15;201(8):2331-2344.
  4. Plantamura E, Dzutsev A, Chamaillard M, Djebali S, Moudombi L, Boucinha L, Grau M, Macari C, Bauché D, Dumitrescu O, Rasigade JP, Lippens S, Plateroti M, Kress E, Cesaro A, Bondu C, Lina G, Bentaher-Belaaouaj A, Marie J, Caux C, Trinchieri G, Marvel J, Michallet MC. (2018) MAVS deficiency induces gut dysbiotic microbiota conferring a pro-allergic phenotype. Proc Natl Acad Sci U S A. Oct 9;115(41):10404-10409. 
  5.  Fourneaux C, Dubois B. (2018) Contribution of B lymphocytes in acquired resistance to targeted therapies in metastatic melanoma. Med Sci (Paris). 34(10):875-878.
  6. Andrieu N, Bendriss-Vermare N. (2018) Immunotherapy and targeted therapy, a promising combination to fight cancer. Med Sci (Paris). 34(10):872-875.
  7. Bossennec M, Di Roio A, Caux C, Ménétrier Caux C. (2018) MDR1 in immunity: friend or foe? OncoImmunology September 7;7 : e1499388-1-11.
  8.  Faure-Dupuy S, Vegna S, Aillot L, Dimier L, Esser K, Broxtermann M, Bonnin M, Bendriss-Vermare N, Rivoire M, Passot G, Lesurtel M, Mabrut J-Y, Ducerf C, Salvetti A, Protzer U, Zoulim F, Durantel D, Lucifora J. (2018) Characterisation of Pattern Recognition Receptors (PRR) expression and functionality in liver primary cells and derived cell lines. J Innate Immun. 2018 Jul 5:1-10. 
  9. I. Monteiro, S. Vigano, M. Faouzi, I. Treilleux, O. Michielin, C. Ménétrier-Caux, C. Caux, P. Romero, L and de Leval.(2018) CD73 expression and clinical significance in human metastatic melanoma. Oncotarget Jun 1;9(42):26659-26669.
  10. Gourdin N, Bossennec M, Rodriguez C, Vigano  S, Jandus C, Mâchon C, Bauché D, Faget J, Durand I, Chopin N, Tredan O, Marie J, Dubois B, Guitton J, Romero P, Caux C *, Ménétrier-Caux C *.(*co-last authorship). (2018) Autocrine Adenosine regulates tumor polyfunctional CD73+CD4+ effector T cells devoid of immune checkpoints Cancer Research July, 78(13); 3604–18. 
  11. Aillot L, Bonnin M, Ait-Goughoulte M, Bendriss-Vermare N, Maadadi S, Dimier L, Subic M, Scholtes C, Najera I, Zoulim F, Lucifora J, Durantel D. Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells. Antimicrob Agents Chemother. 2018 Mar 27;62(4).
  12. Small M*, Treilleux I*, Couillault C*, Pissaloux D, Picard G, Paindavoine S, Attignon V, Wang Q, Rogemond V, Lay S, Ray-Coquard I, Pfisterer J, Joly F, Du Bois A, Psimaras D, Bendriss-Vermare N, Caux C, Dubois B*, Honnorat J*, Desestret V* (*co-last authorship). (2018). Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. 2018 Apr;135(4):569-579.
  13. Hacini F., Gomez de Agüero M., Kanjarawi R., Moro-Sibilot L., Le Luduec J.B., Macari C., Boschetti G., Bardel E., Langella P., B. Dubois* & D. Kaiserlian* (*co-last authorship) (2018). Intestinal dendritic cell licensing through TLR4 is required for oral tolerance in allergic contact dermatitis. J Allergy Clin Immunol., 141(1): 163-170.

2017


  1. Combes A, Camosseto V, N’Guessan P, Argüello RJ, Mussard J, Caux C, Bendriss-Vermare N, Pierre P & and Gatti E (2017). BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells. Nature Comm. 8(1):913.
  2. Mazet J, Michallet MC. (2017). Neutrophil: an infiltrated agent with new antitumor skills. Med Sci (Paris) 33(8-9): 744-47.
  3. Richaud M and Bendriss-Vermare N. (2017). Cancer immunotherapy via systemic RNA delivery to dendritic cells. Med Sci (Paris). 33(10):852-856.
  4. Seillet C and Dubois B. (2017) Infiltrated B cells promote pancreatic ductal adenocarcinoma. Med Sci (Paris) 33(10): 859-862.
  5. Vanacker H, Vetters J, Moudombi L, Caux C, Janssens S, Michallet MC. (2017) Emerging role of the Unfolded Protein Response in Tumor Immunosurveillance. Trends Cancer. 3(7): 491-505.
  6. Hirsch I, Janovec V, Stranska R, Bendriss-Vermare N. (2017) Cross Talk between Inhibitory Immunoreceptor Tyrosine-Based Activation Motif-Signaling and Toll-Like Receptor Pathways in Macrophages and Dendritic Cells. Front Immunol. Apr 7;8:394. 
  7. Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P. (2017) The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 28(8): 1934-41. 
  8. Shekarian T, Valsevia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, Marabelle A. (2017) Pattern Recognition Receptors: Immune Targets to Enhance Cancer Immunotherapy. Ann Oncol. 28(8): 1756-66.
  9. Shekarian T and Valsesia-Wittmann S. (2017) Considerations for the Development of Innovative Therapies against Aggressive Neuroblastoma: Immunotherapy and Twist1 Targeting. Neuroblastoma. InTech open science  145-157.

2016

  1. Le KS, Thibult ML,Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, Broussais F, Bouabdallah R, Colisson R, Caux C, Ménétrier-Caux C, Leroux D, Xerri L and Olive D (2016). Follicular lymphoma B cells generate functional regulatory T cells via ICOS/ICOSL pathway and are inhibited by intratumoral Tregs Cancer Res. in press.
  2. PAN H, Gazarian A, Dubernard JM, Belot A, Michallet MC*, Michallet M* ( *co-last authorship). Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages and Potential Strategies. Frontiers in Immunology in press.Le Luduec JB, Debeer S, Piras F, Andréoni C, Boudet F, Laurent P, Kaiserlian D, Dubois B. (2016) Indradermermal vaccination with un-adjuvanted sub-unit vaccines triggers skin innate immunity and confers protective respiratory immunity in domestic swine. Vaccine 34: 914-922.
  3. Moro-Sibilot L, This S, Blanc P, Sanlaville A, Sisirak V, Bardel E, Boschetti G, Bendriss-Vermare N, Defrance T, Dubois B, Kaiserlian D. Plasmacytoid dendritic cells are dispensable for non-infectious intestinal IgA responses in vivo.  Eur J Immunol. 2016 Feb;46(2):354-9.
  4. Duraes FV, Lippens C, Steinbach K, Dubrot J, Brighouse D, Bendriss-Vermare N, Issazadeh-Navikas S, Merkler D, Hugues S. (2015) pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation. J Autoimmun. 2016 Feb;67:8-18.

2015

  1. Verronèse E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, Ray-Coquard I, Bachelot T, N’Kodia A, Bardin C, Rigal C, Pérol D, Caux C*, Ménétrier-Caux C* ( *co-last authorship) (2015) Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. OncoImmunology 5(3):e1100791.
  2. Dezutter-Dambuyant C, Durand I, Alberti L, Bendriss-Vermare N, Valladeau-Guilemond J, Duc A, Magron A,  Morel AP, Sisirak V, Rodriguez C, Cox D, Olive D, Caux C. (2015) A novel regulation of PD-1 Ligands on Mesenchymal Stromal Cells through MMP-mediated proteolytic cleavage. OncoImmunology 5(3):e1091146.
  3. Ghirelli C, Reyal F, Jeanmougin M, Zollinger R, Sirven P, Michea P, Caux C, Bendriss-Vermare N, Donnadieu MH, Caly M, Fourchotte V, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X, Soumelis V. (2015). Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. Cancer Res. 75(14):2775-87.
  4. Trédan O≠, Ménétrier-Caux C≠, Ray-Coquard I≠, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot, Rigal C, N’Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY*, Caux C* (≠co-first authorship, * co-last authorship).  (2015) ELYPSE-7: A randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann Oncol. 26(7):1353-62.
  5. Dupuis-Maurin V, Brinza L, Baguet J, Plantamura E, Schicklin S, Chambion S, Macari C, Tomkowiak M, Deniaud E, Leverrier Y, Marvel J*, Michallet MC*. (*co-last authorship) (2015) Overexpression of the transcription factor Sp1 activates the OAS-RNAse L-RIG-I pathway. Plos One. 10(3):e0118551.
  6. Pan H, Gazarian A, Buff S, Solla F, Gagnieu MC, Leveneur O, Watrelot-Virieux D, Morisset S, Sobh M, Michallet MC, Roger T, Dubernard JM, Michallet M. (2015) Oral cyclosporine A in neonatal swines for transplantation studies. Immunopharmacology and Immunotoxicology. 37(1):19-25.
  7. Mathieu AL, Verronese E, Rice GI,Fouyssac F, Bertrand Y, Picard C, Chansel M, Walter JE, Notarangelo LD,  Butte M, Nadeau KC, Csomos K, Chen DJ, Chen K, Delgado A, Rigal C, Bardin C, Schuetz C, Moshous D, Reumaux H, Plenat F, Phan A, Zabot M, Balme B,Viel S, Bienvenu J, Cochat P, van Der Burg M, Caux C, Kemp H, Rouvet I, Malcus C, Crow YJ,Fabien N, Ménétrier-Caux C, De Villartay JP, Walzer T and Belot A. (2015) PRKDC mutations associated with immunodeficiency, granuloma and AIRE-dependent auto-immunity. J Allergy Clin Immunol. 135(6):1578-88.e5.

2014

  1. Dutour A, Josserand V, Jury D, Guillermet S, Decouvelaere AV, Chotel F, Pointecouteau T, Rizo P, Coll JL, Blay JY. (2014) Targeted imaging of αvβ3 expressing sarcoma tumor cells in vivo in pre-operative setting using near infrared: A potential tool to reduce incomplete surgical resection. Bone. 62:71-8.
  2. Deauvieau F, Ollion V, Doffin AC, Verronese E., Durand I, Ghittoni R, Marvel J, Walzer T, Vie H., Perrot I., Goutagny N., Caux C*. and Valladeau-Guilemond J*. (2014) Human natural killer cells promote tumor cell-derived antigen cross presentation by dendritic cells through cytokine production. Int J Cancer 136(5):1085-94. *co-senior authors
  3. Zannetti C, Parroche P, Panaye M, Roblot G, Gruffat H, Manet E, Debaud AL, Plumas J, Vey N, Caux C, Bendriss-Vermare N, Hasan UA. TLR9 transcriptional regulation in response to double-stranded DNA viruses. J Immunol. 2014 Oct 1;193(7):3398-408.
  4. Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, Vu Manh T-P, Sanchez C, Savoret J, Perrot I, Doffin AC, Fossum E, Bechlian D, Chabannon C, Bogen B, Asselin-Paturel C, Shaw M, Soos T, Caux C, Valladeau-Guilemond J*, Dalod M*. (2014) Human XCR1+ DC derived in vitro from CD34+ progenitors closely resemble blood DC including by their adjuvant responsiveness, contrary to monocyte-derived DC. J Immunol. 193(4):1622-35.*co-senior authors

2013

  1. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. (2013). Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 123:2447-2463.
  2. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N. (2013). Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 73:4629-4640
  3. El Sayadi H, Pissaloux D, Alberti L, Tabone-Eglinger S, Ranchere D, Decouvelaere AV, Tabone E, Ray-Coquard I, Caux C, Fayette J, Blay JY.  (2013) Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. Target Oncol. 8:261–269
  4. Bachet JB, Tabone-Eglinger S, Dessaux S, Besse A, Brahimi-Adouane S, Emile JF, Blay JY, Alberti L. (2013). Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples. PLoS One. 8:e61103
  5. Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I,  Clapisson  G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Ménétrier-Caux C, Blay JY. (2013) CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer 49:1080-1089.
  6. Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, and Bendriss-Vermare N.  (2013) Breast cancer-derived TGF-b and TNF-a compromise IFN-a production by tumor-associated plasmacytoid dendritic cells. Int J Cancer. 133:771-778.
  7. Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, and Ménétrier-Caux C. (2013) ICOS is associated with poor prognosis through immuno-suppressive CD4 T cell amplification by plasmacytoid DC in breast tumours. OncoImmunology 2:e23185
  8. Sisirak V, Faget J, Vey N, Blay JY, Ménétrier-Caux C, Caux C and Bendriss-Vermare N.  (2013) Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients OncoImmunology 2:e22338.
  9. Tredan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C and Ménétrier-Caux C. (2013). Patients with metastatic breast cancer leading to CD4+ T cell Lymphopenia have poor outcome. Eur J Cancer 49:1673-1682.2012

2012 

  1. Caux C. and Zitvogel L. Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Targeted Oncol.  7:1-2, 2012.
  2. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting Pattern Recognition Receptors in cancer immunotherapy. Targeted Oncol. 7:29-54, 2012.
  3. Labidi-Galy S.I., Treilleux I., Goddard-Léon S., Combes J.D., Blay J.Y., Ray-Coquard I., Caux C., and Bendriss-Vermare N. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. OncoImmunology, 1(3):379-81, 2012.
  4. Manuel M, Tredan O, Bachelot T, Clapissson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY and Ménétrier-Caux C. Lymphopenia Combined with low TCR Diversity (divpenia) predicts poor Overall Survival in Metastatic Breast Cancer Patient. OncoImmunology, 1(4):433-42, 2012.
  5. Marabelle A,Caux C. Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine. Blood. 2012 Nov 29;120(23):4454-5. doi: 10.1182/blood-2012-09-455105.
  6. Ménétrier-Caux C, Faget J, Biota C, Gobert M, Blay JY and Caux C. Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. OncoImmunology, 1(5):759-61, 2012.
  7. Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C and Zou W. Targeting regulatory T cells. Targeted Oncol. 7:15-28, 2012.
  8. Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, Pourchet J, Puisieux I, Browne GJ, Spicer DB, Lachuer J, Ansieau S and Puisieux A. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. Plos Genetics. 8(5): e1002723, 2012.
  9. Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Ménétrier-Caux C, Blay JY CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer 2012.
  10. Ray-Coquard I, Chauvin F., Leblanc E.  Caux C., Hoarau H., Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, Joly F. Le PAIR-gynécologie : recherche multi/interdisciplinaire en cancérologie gynécologique. Les problèmes à résoudre en 2012. Bull Cancer. 99(4):479-498, 2012.
  11. Trédan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-Dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Ménétrier-Caux C. Patients with metastatic breast cancer leading to CD4(+) T cell lymphopaenia have poor outcome. Eur J Cancer. 2012 Dec 19.
  12. Segura E., Valladeau-Guilemond J., Donnadieu MH, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med. 209:653-60, 2012.

2011

  1. Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Menetrier-Caux C, Tredan O, Goddard-Leon S, Pin JJ, Mignotte H, Barthelemy-Dubois C, Caux C, Lebecque S, Blay JY. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer. 11:213-23, 2011.
  2. Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Römer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Gutierrez JC, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, Vivier E, Lecesne A, Kroemer G, Zitvogel L. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 17:700-7, 2011.
  3. Faget J., Biota C., Bachelot T., Gobert M., Treilleux I., Goutagny N., Durand I., Léon-Goddard S.,  Blay J.Y., Caux C. and Ménétrier-Caux C. Early detection of tumor cells by innate immune cells leads to Treg recruitment through CCL22 production by tumor cells. Cancer Res. 71:6143-52, 2011.
  4. Gougelet A, Perez J, Pissaloux D, Besse A, Duc A, Decouvelaere AV, Ranchere-Vince D, Blay JY, Alberti L. miRNA Profiling: How to Bypass the Current  Difficulties in the Diagnosis and Treatment of Sarcomas. Sarcoma. 2011:1-14, 2011.
  5. Labidi-Galy SI, Ray-Coquard I, Sisirak V, Treilleux I, Meeus P, Mithieux F, Bajard A, Combes JD, Gobert M, Faget J, Guastalla JP, Tredan O, Ménétrier-Caux C, Caux C, Blay JY and Bendriss-Vermare N.Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 171:5423-34, 2011.
  6. Labidi-Galy S.I., Faget J., Treilleux I., Ménétrier-Caux C., Caux C., and Bendriss-Vermare N. Immunologie du cancer de l’ovaire : de la théorie à la thérapeutique. "Cancer de l’ovaire" Edition 2, (Edition : Springer), chapter book, pp 613-626, 2011.
  7. Perez J., Bardin C., Rigal C., Besse A., Rousseau R., and Dutour A. Anti MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res. 31(9):2813-20, 2011.
  8. Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, Bowman EP, Trinchieri G, Dubois B,  Kaiserlian D, Lira SA, Puisieux A, Blay JY, Caux C, and Bendriss-Vermare N. CCR6/CCR10-mediated plasmacytoid dendritic cells recruitment to inflamed epithelia following instruction in lymphoid organs. Blood. 118(19):5130-40, 2011.

BREVET: Antibodies directed against ICOS and uses thereof. Filed May 2011, n° EP11305385.5. Inventors: JULIEN FAGET, MÉNÉTRIER-CAUX CHRISTINE, JACQUES NUNES, DANIEL OLIVE, CAUX CHRISTOPHE

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :